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ABSTRACT
Background To evaluate the safety, tolerability,
pharmacokinetics and pharmacodynamics of eftilagimod
alpha (efti), a soluble lymphocyte activation gene-3 protein,
in combination with the programmed cell death-1 (PD-1)
antagonist pembrolizumab.
Methods The study was divided into two parts; parts
A and B, where part A was the dose escalation part
and part B was an extension part of the study. Patients
with metastatic melanoma were treated with efti plus
the standard dose of pembrolizumab. Blood samples
were assayed to determine plasma pharmacokinetic
parameters, detect efti antibody formation and determine
long-lived CD8 T cell responses and associated
pharmacodynamic parameters.
Results Twenty-four patients with melanoma received
pembrolizumab and bi-weekly subcutaneous (s.c.)
injections of efti at doses 1 mg, 6 mg or 30 mg/injection
for up to 6 months (part A) or 30 mg/injection for up 12
months (part B). No dose-limiting toxicities were reported
and the main adverse event for efti was injection site
reactions. Sustained systemic exposure to the product was
obtained in all patients following s.c. injections of 30 mg
dose. Treatment induced an increase in activated CD8 and
CD4 T cell counts, and in some of the soluble biomarkers,
particularly interferon (IFN)-γ, a Th1 signature cytokine.
An overall response rate (ORR) of 33% was observed in
patients partly with pembrolizumab-refractory of part A
and ORR of 50% was observed in patients with PD-1 naïve
of part B.
Conclusions Efti was well tolerated in combination with
pembrolizumab with encouraging antitumor activity. This
warrants further clinical studies of this new combination
therapy combining an antigen-presenting cell activator
with an immune checkpoint inhibitor.

INTRODUCTION
Antigen-
presenting cell (APC) activators
are a type of immunotherapy that leverages APC to drive an adaptive immune
response. Combinatorial approaches that
target multiple aspects of the cancer immunity cycle,1 including APC activation, are

promising strategies for the treatment of
cancer. Professional APCs express major
histocompatibility complex (MHC) class II
and CD40 molecules as surface receptors
and can be activated through direct interactions with T cells expressing these receptors’
corresponding ligands, lymphocyte activation
L, respectively.
gene-3 (LAG-3) and CD40-
A third class of receptors that can activate
like receptors (TLRs)
APCs are called toll-
and bind foreign ligands that are structurally
conserved molecules from microbes. Interest
in the clinical use of TLR and CD40 agonistic
antibodies in immuno-oncology wavered in
the past decade,2 but recent clinical data are
encouraging.3–5
The MHC class II agonist eftilagimod
alpha (efti, IMP321 or LAG-3Ig) is a soluble
LAG-3 protein that activates APC leading
to CD8 T-
cell activation.6–8 Efti binds to a
subset of MHC class II molecules expressed
in plasma membrane lipid rafts on immature
human dendritic cells (DCs) and induces
rapid morphological changes, including
the formation of dendritic projections.6 7 It
also markedly upregulates the expression of
costimulatory molecules and the production
of IL-12 and tumor necrosis factor (TNF)α.6 7 In patients with cancer, efti has been
shown to sustain the generation and expansion of tumor antigen (melan-A/melanoma
antigen recognized by T cells 1 (MART-1)
and survivin)-specific CD8+ T lymphocytes in
peripheral blood mononuclear cells (PBMC),
showing its ability to boost CD8+ T cell
memory response ex vivo.9 Phenotype and
cytokines/chemokines produced by APC of
PBMC exposed ex vivo for 2 days to peptide
and efti indicate that the LAG-3-
mediated
effect depends on a direct activation of circulating APCs.9
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Figure 1 Effect of efti versus an anti-LAG-3 antagonist
antibody on the immune response. LAG-3, lymphocyte
activation gene-3.

The addition of pembrolizumab as an immune checkpoint inhibitor (ICI) aims at enhancing activity by
combining efti’s activating effects on immune cells with
the release of immune inhibitory effects caused by interruption of the programmed death-1 (PD-1)/programmed
death ligand-1 axis. The present TACTI-
mel (“Two
ACTive Immunotherapies in melanoma”) phase I trial is
testing this combined push (systemic APC activation) and
pull (ICI) approach in metastatic melanoma. This therapeutic approach is fundamentally different from the
mainstream two-ICI approach (ie, anti-LAG-3+anti-PD-1
monoclonal antibody (mAbs)) as efti is an agonist acting
on APC and anti-LAG-3 mAb is an antagonist acting on T
cells, see figure 1.

MATERIALS AND METHODS
Study design and treatments
This was a multicenter, open-label, dose escalation, phase
I study in patients with unresectable or metastatic melanoma receiving efti in combination with anti-PD-1 therapy
with pembrolizumab.
In part A, screening was done in parallel to cycle 4 of
actively ongoing pembrolizumab therapy and treatment
with efti was started with cycle 5 of pembrolizumab.
Pembrolizumab was given at a dose of 2 mg/kg intravenous every 3 weeks; efti was given as subcutaneous (s.c.)
injection of 1 mg (cohort 1), 6 mg (cohort 2) or 30 mg
(cohort 3) every 2 weeks for approximately 6 months,
starting with cycle 5 of pembrolizumab. The study design
for part A is shown in figure 2.
Three sequential dose escalation cohorts of six patients
each were evaluated for dose-limiting toxicities (DLTs)
according to Common Terminology Criteria for Adverse
Events (CTCAE) V.4.03. The evaluation for DLTs was
performed in the safety observation period (from the
first study treatment until 24 hours after the third efti
injection). Decisions for dose escalation and determination of the recommended dose for part B were based
on all safety data collected during the safety observation
period and made by the Data and Safety Monitoring
Board.
In part B, patients received pembrolizumab (2 mg/
kg intravenous every 3 weeks) in conjunction with efti
s.c. at the recommended dose of 30 mg every 2 weeks
for a maximum of 12 months, starting with cycle 1 of

Figure 2 Study design of parts A and B. Tumor assessment was done every 12 weeks in both parts. Pembrolizumab could
be continued after combination therapy with efti was finished. Pembrolizumab was administered intravenous 2 mg/kg. efti was
administered s.c. Part A (top): patients with irPD or suboptimal response (ie, irSD or PR) after 3 cycles of pembrolizumab were
screened during cycle 4 of pembrolizumab therapy. Eligible patients received efti (1, 6, 30 mg) with cycle 5 of pembrolizumab for
up to 6 months. Part B (bottom): patients received efti (30 mg) with cycle 1 of pembrolizumab for up to 12 months. ORR, overall
response rate; PFS, progression-free survival; TACTI, Two ACTive Immunotherapies.
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pembrolizumab treatment. Patients were also evaluated
for DLTs according to CTCAE V.4.03.
Study assessments
The primary objective of the study was to evaluate the
safety, tolerability and recommended phase two doseof
efti when combined with anti-
PD-1 treatment starting
with cycle 5 (part A) or cycle 1 (part B) of pembrolizumab. The primary endpoint was safety as defined by the
frequency, severity and duration of adverse events (AEs)
including serious AEs (SAEs) and DLTs and other safety
parameters.
Tumor response and progression were assessed using
immune-related response criteria (irRC) and Response
Evaluation Criteria in Solid Tumors (RECIST V.1.1) with
imaging studies done every 12 weeks. Blood samples were
collected for analysis of plasma concentrations of efti and
cytokines/chemokines and for detection of serum anti-
efti antibodies. EDTA-whole blood samples were collected
for monitoring the T cell immune responses.
Pharmacokinetic analysis
Pharmacokinetic analysis was performed using a validated
method on plasma samples collected up to 48 hours post
the 1st and 13th efti dosing in the dose escalation part.
Efti concentration was assessed using an LAG-3-specific
ELISA using a pair of mouse monoclonal anti-human
LAG-3 antibodies, 11E3 and biotin-conjugated 17B4 as
capture and detection reagent, respectively. The lower
limit of quantification was determined at 105 pg/mL.
Pharmacokinetic parameters were derived using noncompartmental analysis with Phoenix WinNonlin V.7.0 software (Certara).
Cytokines/chemokines assessment
Panels of 9 cytokines and 10 chemokines were assessed in
plasma samples collected prior and 1, 2, 4, 8, 24 and 48
hours post the 1st and the 13th efti administration in part
A patients. In outline, the analytical method consists of a
validated multiplexed electrochemiluminescence immunosorbent assay (ECLIA) using commercial kits (human
proinflammatory panel 1 and chemokines panel 1 V—
plex MesoScale Discovery kits). Manufacturer instructions
were followed with minor modifications and lower limits
of quantification were determined at 6.1, 1.6, 5.3, 0.8, 0.7,
0.7, 0.5, 2.9, 7.5, 1.3, 7.5, 34.2, 3.5, 6.4, 9.8, 2.4, 3.7, 27.6,
8.2 pg/mL for interferon (IFN)-γ, IL-1β, IL-2, IL-4, IL-6,
IL-8, IL-10, IL-12p70, IL-13, TNF-α, eotaxin, eotaxin-3,
Thymus and activation-
regulated chemokine (TARC),
Interferon gamma-
induced protein 10 (IP-10), Macrophage inflammatory protein (MIP)-1α, MIP-1β, Monocyte
chemoattractant protein (MCP)-1, Macrophage-derived
chemokine (MDC) and MCP-4, respectively.
Detection of anti-efti antibodies
Serum samples were planned pretreatment and at end
of treatment visit for all patients. Additionally, patients
participating to the part B of the study were sampled
after about 1, 2, 3, 6 and 9 months at cycles 2, 3, 5, 9, 13
Atkinson V, et al. J Immunother Cancer 2020;8:e001681. doi:10.1136/jitc-2020-001681

always predose. A fully validated three tiers conventional
bridging ECLIA method with a screening assay (tier 1),
a confirmatory assay (tier 2) and titration assay (tier 3)
were used. Briefly, anti-
efti antibodies were captured
and detected in a sandwich formed by biotinylated and
ruthenylated efti. Such complexes are then captured by
a streptavidin-coated plate and processed for ECL signal
detection. An affinity purified rabbit anti-
LAG-3 polyclonal antibody was used as positive control. The sensitivity was determined at 78 ng/mL in a pooled serum
matrix and confirmed at 250 ng/mL in 20 individual
serum. The free drug tolerance was found to be approximately 500 ng/mL of free drug for 250 ng/mL of positive
control. Thus, given the low level of circulating drug (<20
ng/mL), drug tolerance was acceptable for the intended
purpose.
Pharmacodynamics
EDTA-whole blood samples were collected at cycle 1, cycle
5, cycle 9 and cycle 13 (in part B only) prior to treatment
(therefore 2 weeks after the previous dosing) and EOT.
Direct blood staining with BD Multitest CD8-FITC (clone
SK1)/CD38-PE (clone HB7)/CD3-PerCP (clone SK7)/
HLA-DR-APC (clone L343) was performed to enumerate
ex vivo the absolute counts of activated T CD3+CD8+ or
CD3+CD8- cells coexpressing HLA-DR and CD38 in BD
Trucount tube with a lyse/no wash procedure, avoiding
any bias induced by centrifugation steps. Cells were
acquired on BD FACSCanto II flow cytometer. The paired
nonparametric Wilcoxon-
signed rank test was used to
compare the immunomonitoring results obtained at the
different time points to the pre-treatment baseline using
JMP V.12 software.
In vitro antigenic T-cell response assessment
PBMCs from healthy donors (0.2×106 cells/well in
round-
bottom 96-
well plate, at 1×106/mL in complete
RPMI+10% fetal calf serum) incubated with a pool of
peptides covering the sequence of cytomegalovirus (CMV)
pp65 in triplicate (PepTivator CMV pp65 form Miltenyi
Biotec), with or without efti and/or an antagonist anti-
PD-1 antibody (clone EH12.1, BD Biosciences) as indicated in figure 2 legend in complete RPMI. After 2 days,
cells and/or supernatant were collected and cytokines/
chemokines were assessed by Cytometric Bead Array flex
set (BD Biosciences) to measure concentrations of cytokines in the supernatant. In other series of experiments,
PBMCs were stimulated as above and cells were collected
to be stained with a mix of the following conjugated antibodies to determine expression of activation markers.
Anti-CD14-APC (clone MφP9), Anti-CD4-PerCPCy5.5
(clone L200), anti-CD8-PE (clone RPA-T8), anti-CD25-
PECy7 (clone M-251), anti-CD69-APCCy7 (clone FN50)
were purchased from BD Biosciences. Antibody staining
was performed at 4°C during 30 min in phosphate buffered saline (PBS), bovine serum albumine (BSA) 0.5%,
azide 0.1%. Data were collected on a FACS Canto A and
CD14−CD8+ and CD14−CD4+ gated populations were
3
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analyzed on DIVA software (BD Biosciences). Comparisons of combined cell treatment to treatment with single
agents were analyzed by Student’s t-test.
Statistical analysis
Safety: Analyses of safety parameters were performed
using descriptive statistics.
Efficacy: Assessments of tumor response were based
on investigator assessment according to Guidelines
for the Evaluation of Immune Therapy Activity in
Solid Tumors: irRC/RECIST V.1.1. Analyses of tumor
response endpoints were performed based on unconfirmed responses (main analysis) and additionally also on
confirmed responses, for both RECIST V.1.1 and irRC.
In parts A and B, response was assessed using as baseline
the start of pembrolizumab and efti combination therapy.
Additional exploratory analyses were performed for part
A, using the start of pembrolizumab treatment as baseline. For this exploratory immune related Best Overall
Respons (irBOR), the sum of target lesions prior to
pembrolizumab therapy initiation was used as a reference
for each patient.
Efficacy analyses and exploratory endpoints were generally performed using descriptive statistics. Progression-
free survival (PFS) was analyzed using Kaplan-
Meier
methods.

RESULTS
In vitro proof-of-concept for combined therapy (anti-PD1+efti)
The combination of efti as an APC-activator with an ICI
to boost the immune response was evaluated in vitro by
monitoring the antigenic T-cell response of human PBMC
stimulated with an antigenic peptides pool in the presence of efti and anti-PD-1 antibody. Cellular response was
monitored by assessing the concentration of IFN-γ, TNF-α
and RANTES in cell supernatants or the expression of
activation markers (CD69, CD25) on CD8 T cell surface
(figure 3). High concentration (1000 ng/mL) of anti-
PD-1 antibody was also used as additional control. The
immune response induced by the combination of efti and
anti-PD1 antibody was more pronounced as fold increase
than the sum of the effects obtained after incubation with
a single agent. The response to combined treatment was
also greater than the one observed with PD-1 blocker at
30-fold higher concentration. The effect of efti addition
in an anti-PD-1 antibody dose–response experiment led
to a similar observation (figure 3C).
Patients
The study was divided into two parts; parts A and B,
where part A was the dose escalation part and part B was
a dose confirmation part of the study. Patients were to
stay on treatment until confirmed disease progression,

Figure 3 Effect of efti plus anti-PD-1 combination on antigen-induced human T cell response. CMV-stimulated PBMCs from
healthy donors were incubated in the presence of 0 or 30 ng/mL efti and in the presence of 0, 30 or 1000 ng/mL anti PD-1
antagonist antibody as indicated. Two days post-stimulation, supernatants were collected and concentration of IFN-γ, TNF-α
and RANTES was measured (A). The expression of activation markers, CD69 and CD25 at the surface of CD8+ T cells was
analyzed by flow cytometry (B). The results are shown in fold increase of levels of soluble biomarkers or the % of CD8 T cells
expressing the indicated marker in the indicated condition to the value obtained in the absence of efti and anti-PD-1 antibody.
Bars represent average of 10 donors for soluble analytes and seven donors for activation markers. Significant difference
(p<0.05) between combined condition to either efti or anti-PD-1 Ab alone is displayed by a bar on the top of each graph.
Panel (C) shows the IFN-γ concentration in cell supernatants of an anti-PD-1 dose–response experiment, either alone (opened
markers, dashed lines) or combined with 30 ng/mL efti (close markers, plain lines), carried out with PBMC from three donors.
The results are shown in fold increase of IFN-γ levels as a function of anti-PD-1 antibody concentration. CMV,cytomegalovirus;
IFN, interferon; PBM, peripheralblood mononuclear; PD-1, programmed death-1.
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unacceptable toxicity, completion of the study or discontinuation for any other reason whichever occurred first.
The study was conducted at seven sites across Australia.
Main inclusion criteria were histologically confirmed
unresectable stage III or stage IV melanoma; Eastern
Cooperative Oncology (ECOG) 0–1; measurable disease
according to RECIST 1.1 and adequate laboratory values.
Main exclusion criteria were prior PD-1/programmed
death ligand-1 (PD-L1) therapy (for part A, patients were
on pembrolizumab therapy at the time of screening),
known cerebral or leptomeningeal metastases (stable
previously treated brain metastases allowed) or continuous corticotherapy (>10 mg/day prednisone equivalent) within 4 weeks prior to study start.
Part A
Eighteen patients were included in part A of the study. All
patients had stage IV melanoma. Disease stage at baseline
was M1c in 14 patients (77.8%), M1b in 3 patients (16.7%)
and M1a in 1 patient (5.6%). In 38.9% of patients, lactate
deshydrogenase (LDH) was elevated at study entry. Of
27.8% had received prior anticancer medications, that
is, three patients had received dabrafenib and trametinib
and two patients had received ipilimumab. All patients
of part A were receiving pembrolizumab at the time of
screening. ECOG PS at screening was 0 in 14 patients
(77.8%) and 1 in 4 patients (22.2%). Almost all patients
(94.4%) were men; all patients were Caucasian. Median
age was 66.7 years. Patients were required to have asymptomatic immune-
related progressive disease (ie, slowly
progressive disease, not requiring urgent intervention and
stable performance status) or suboptimal response (ie,
immune-related stable disease (irSD) or partial response
(irPR)) after three cycles (≈9 weeks) of pembrolizumab.
Part B
Part B was a six-patient toxicity lead-in cohort. All patients
had stage IV melanoma. Stage of disease was M1c in four
patients (66.7%) and M1b in two patients (33.3%). In
80% of patients, LDH was elevated at study entry. ECOG
PS at screening was 0 and 1 in three patients (50.0%) each.
Almost all (five patients, 83.3%) were men; all patients

were Caucasian. Median age was 65.0 years. Most patients
(83.3%) had undergone prior anticancer surgery; one
(16.7%) had received prior anticancer radiation; none
had received prior systemic anticancer medication.
Safety
Part A
The planned number of 13 efti doses was given in six
patients (33%). Main reason for discontinuation was
progression (n=7; 39 %). The median number of efti
injections was 8 in the 1 mg and 6 mg cohorts and 12
in the 30 mg cohorts. Median treatment duration with
efti was 98 days in the 1 mg and 6 mg cohorts and 161
days in the 30 mg cohort. No DLTs were reported. None
of the AEs led to discontinuation of efti or pembrolizumab. SAEs were reported in six patients (33%); none
as being drug related. The most frequent AEs regardless
of relationship are listed in table 1. Nine patients (50.0%)
reported AEs (possibly) related to efti. AEs reported
in more than single patients were fatigue (11.1%) and
rash (11.1%). Thirteen patients (72.2%) reported AEs
(possibly) related to pembrolizumab. AEs reported in
more than single patients were fatigue (27.8%), nausea
(16.7%), diarrhea (11.1%,), pruritus (11.1%), arthralgia
(11.1%), colitis (11.1%) and rash (11.1%).
Part B
Of six patients, three patients (50%) received all 27 doses
of efti according to the protocol. Two patients discontinued due to progressive disease and one due to an
AE. The median number of injections in part B was 24.
Median treatment duration with efti in part B was 322
days. DLTs were not reported. One SAE of anaphylactic
reaction (grade 3) was judged as efti related; this patient
discontinued efti because of the event. The most frequent
AEs regardless of relationship are listed in table 1. Five
patients (83.3%) reported AEs (possibly) related to efti.
AEs reported in more than single patients were injection
site erythema (66%), injection site swelling (50%) and
injection site pain (33%). Five patients (83.3%) reported
AEs that were (possibly) pembrolizumab related. AEs

Table 1 Most frequent (≥4 or more patients in part A and/or >3 pts in part B) treatment-related adverse events
Part A

Part B

Efti (1 mg)/
pembro (n=6)

Efti (6 mg)/
pembro (n=6)

Efti (30 mg)/
pembro (n=6)

Total
(n=18)

Efti (30 mg)/
pembro (n=6)

Fatigue
Injection site erythema

4 (66.7)
–

1 (16.7)
–

3 (50.0)
1 (16.7)

8 (44.4)
1 (5.6)

5 (83.3)
4 (66.7)

Edema peripheral

–

–

–

–

4 (66.7)

Diarrhea

2 (33.3)

–

3 (50.0)

5 (27.8)

1 (16.7)

Nausea

1 (16.7)

2 (33.3)

2 (33.3)

5 (27.8)

2 (33.3)

Rash
Arthralgia

1 (16.7)
2 (33.3)

2 (33.3)
1 (16.7)

2 (33.3)
1 (16.7)

5 (27.8)
4 (22.2)

4 (66.7)
4 (66.7)

Results shown as: number of patients with adverse event (%).

Atkinson V, et al. J Immunother Cancer 2020;8:e001681. doi:10.1136/jitc-2020-001681

5

J Immunother Cancer: first published as 10.1136/jitc-2020-001681 on 20 November 2020. Downloaded from http://jitc.bmj.com/ on February 8, 2021 at Edith Cowan University. Protected by
copyright.

Open access

patients treated for at least 2 months were ADA-positive.
Relatively high titres were observed in two patients of six
(up to 666), while other patients had low titer (<32). No
obvious relationship could be observed between immunogenicity and pharmacodynamics parameters. ADA
occurrence and intensity did not negatively impact the
clinical response read-outs.
Figure 4 PK profiles. PK profiles from patients receiving
1 mg (left panel), 6 mg (middle panel) or 30 mg (right panel)
are shown. Soluble LAG-3 was measured by ELISA in the
plasma at different time points following the first (plain lines)
or the 13th (dashed lines) s.c. injection. LAG-3, lymphocyte
activation gene.

reported in more than single patients were rash (50%);
and fatigue, arthralgia and pruritus (each 33%).
Pharmacokinetic analysis
A dose-
proportional maximal exposure was observed
across all dose levels. The results of the pharmacokinetics
analysis for the three dose groups are shown in figure 4.
After administration of efti 30 mg, all patients reached
a circulating plasma concentration of efti/soluble LAG-3
(sLAG-3)>1 ng/mL, while only half of the patients
receiving efti 6 mg and none from the efti 1 mg cohort
reached this threshold. Mean Cmax increased with dose
(for both cycles): 0.26 ng/mL (n=6, 35% CV) for efti 1
mg, 1.95 ng/mL (n=6, 88% CV) for efti 6 mg and 3,52
ng/mL (n=6, 71% CV) for efti 30 mg, in cycle 1. These
values are similar to the ones reported previously with efti
monotherapy.10 In cycle 9, values of 0.24 ng/mL (n=2, 1%
CV) for efti 1 mg, 0.78 ng/mL (n=2, 0.4% CV) for efti 6
mg and 3.43 ng/mL (n=3, 85% CV) for efti 30 mg were
reported.
At first administration, median Tmax was about 14
hours for efti 1 mg and 6 mg and 24 hours for efti 30
mg. In cycle 9, median Tmax decreased with dose: 24.0
hours, 12.6 hours and 4.0 hours for efti 1 mg, 6 mg and
30 mg, respectively. Mean area under the curve (AUC)0-t
was 9195 hour·pg/mL (n=6, 58% CV) for efti 1 mg, 65
674 hour·pg/mL (n=6, 103% CV) for efti 6 mg and 110
753 hour·pg/mL (n=6, 69% CV) for efti 30 mg, in cycle
1; and 6883 hour·pg/mL (n=2, 61% CV) for efti 1 mg, 16
213 hour·pg/mL (n=2, 115% CV) for efti 6 mg, and 92
036 hour·pg/mL (n=3, 94% CV) for efti 30 mg, in cycle 9.
Safety cytokines/chemokines and anti-efti antibodies
Study treatment-
related clinically relevant increases of
plasma levels of at least two cytokines among TNF-α,
IFN-γ, IL-1β, IL-2, IL-4 and IL-8 by >50 times over baseline were considered as DLT. No safety-related increase
in circulating levels cytokines was noted for any patient.
A moderate increase in IL-6 (mean fold change 1.5, 1.7
and 1.6 at 4, 8 and 24 hours, respectively, after the first
dosing at cycle 1, and 1.8, 1.8 and 1.4 at 4, 8 and 24 hours,
respectively, after the last dosing at cycle 9) was observed.
In part A, the percentage of anti-drug antibodies (ADA)-
positive patients increased with the efti dose. In part B, all
6

Pharmacodynamics
Immunomonitoring was done on whole blood samples 2
weeks after efti injection in order to detect the minimal
residual effect of efti just before the next efti injection.
Therefore, any change induced by efti would indicate a
long-term sustained immunostimulation (more than 10
days after efti disappearance in the blood) and for the
T-cell compartment a sustained effect on the memory
T-cell subset.
In part B, which is the study design to be used for future
phase II trials, we found a sustained increase in activated
(CD38+ HLA-DR+) CD4 T cells (1.3, 1.5 and 1.2-median
fold or 1.4, 1.6 and 1.2-mean fold change at day 1 of cycle
5, day 1 of cycle 9 and day 1 of cycle 13, respectively)
or CD8 T cells (2.1, 2.0 and 1.8-median fold or 2.5, 2.0,
1.5-mean fold change) counts compared with the baseline (predose at cycle 1) (figure 5). All part B patients
increased their circulating activated cytotoxic T cells by at
least two-fold after 3 months of treatment and by at least
1.5-fold after 6 months, while in part A, only 4 patients
out of 11 tested showed an increase by more than 1.5-fold
at cycle 5 or cycle 9. Among these 4, 3 received 30 mg
doses (online supplemental figure 1). An increase in NK
cell counts was also observed in part B patients with 1.7-
median fold or 1.6-mean fold at day 1 of cycle 5 and 1.4-
median fold or 1.5-mean fold at day 1 of cycle 9 (online
supplemental figure 1).
In part A patients, the circulating concentrations of
IFN-γ, a Th1 biomarker, were slightly increased at cycle 9
prior to the last dosing, namely, 2 weeks after the previous
efti administration, by a mean of 1.3. IFN-γ concentration
continued to increase up to a mean fold change of 2 at
8 hour after the last dosing of the study drug compared
with the baseline. Chemokine (C-
X-
C motif) ligand
(CXCL-10), another Th1 biomarker, only increased 1.3-
fold, 8–48 hours following the last injection.
Efficacy
In part A, based on the start of efti and pembrolizumab
combination therapy (see figure 3 study PFS/overall
response rate (ORR)), six patients (33%) achieved
ORR (RECIST1.1; unconfirmed) including two patients
(11.1%) with a CR. Both CRs and five responses in total
were confirmed. Disease control rate (DCR) was 55.6%.
Median PFS according to RECIST V.1.1 was reported with
142 days (4.7 months). The probability of being event-
free according to RECIST V.1.1 at 12 months was 35.7%.
The depth of responses is shown in the waterfall plot in
figure 6B. The development over time is displayed in
the spider plot in figure 6A. Results based on irRC were
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J Immunother Cancer: first published as 10.1136/jitc-2020-001681 on 20 November 2020. Downloaded from http://jitc.bmj.com/ on February 8, 2021 at Edith Cowan University. Protected by
copyright.

Open access

Figure 5 Increase of circulating activated cytotoxic and
helper T cells. Absolute counts of circulating CD3+ CD8+
(left panel) and CD3+ CD8- (in practice CD4+ cells, right
panel) T cells coexpressing activation markers HLA-DR
and CD38 were counted in whole blood samples in part B,
prior to dosing at cycle 1 (baseline), at cycles 5, 9 and 13 by
flow cytometry. Results are presented as fold change from
baseline at each time point. Significant changes assessed
by paired nonparametric Wilcoxon signed rank test are
displayed (*p<0.05, **p<0.01).

comparable to those based on RECIST 1.1 with an irORR
of 33 %, including one patient with irCR and five patients
with irPR. The irDCR was 66%. Median PFS based on
irRC was 165 days (5.4 months). The 12 months PFS rate
was 40%. In part A, three of six patients progressing on
pembrolizumab monotherapy benefited from the combination treatment reporting irCR (n=1), irPR (n=1) and
irSD (n=1) as best response under study. Both patients

with a response completed the study treatment. Of the
six patients responding to the combination therapy, two
were progressing, two had a stabilization of disease and
two showed a partial response after 3 cycles of pembrolizumab, respectively.
In part B, ORR (RECIST V.1.1) was 50% (all confirmed)
with a DCR of 83% (see figure 6D). All responses were
ongoing at study end at 12+ months. Thus, median PFS
and median duration of response could not be calculated.
The probability of being event-free at 12 months was 67%.
Results according to irRC were comparable with irORR
(confirmed) was achieved by three patients (50%). irDCR
was 67%. Median PFS (irRC) was not reached; the probability of being event free at 12 months was estimated as
67% as shown in the spider plot in figure 6C.
Efficacy—parts A+B
Exploratory analyses were performed for pooled data
from parts A and B (exploratory irORR/irDCR); baseline
for all patients was the start of pembrolizumab therapy, in
part A and part B (see figure 2). The best overall response
per irRC for each patient of parts A and B including the
duration of pembrolizumab treatment is shown in the
swimmer plot in figure 7. The reported irORR was 54%
and irDCR was 75%.

Figure 6 Best overall response. Spider plot (left; A+C) as per irRC and waterfall plot (right, B+D) as per RECIST 1.1 for part
A (top) and part B (bottom). Best overall response (BOR) as per RECIST1.1/irRC is displayed using the following code: black
represents PD/irPD, gray SD/irSD, hashed gray Pr/irPR while hashed black CR/irCR, respectively. *Nontarget lesions (NTL) still
present; **target lesions (TL) and NTLs disappeared, but new lesions (NL) were present at staging; ***time of CR of TLs; NLs
appeared; staging before was SD (BOR is SD). irPD,immune-related progressive disease; irPR, immune-related partial response;
irSD, immune-related stable disease.
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Figure 7 Swimmer plot with best overall response
according to irRC for all patients of parts A and B. Each
patient is displayed from the start of pembrolizumab therapy.
All four groups are shown with A1=part A, 1 mg efti; A2=part
A, 6 mg efti, A3=part A, 30 mg efti and B=part B, 30 mg efti.
BOR,best overall response; irPD, immune-related progressive
disease; irPR, immune-relatedpartial response; irSD, immune-
relatedstable disease; PFS, progression-free survival.

DISCUSSION
The activation of potent CD8 T-cells with high effector
activity is one of the goals of an effective immunotherapy. The data presented in this report showed a
long-term expansion of an activated CD8 T cell subset
in patients treated with efti and anti-PD-1 combined
therapy. Such finding is in line with other pharmacodynamic observations obtained in other efti clinical
studies.10–13 When efti was used as a monotherapy, it
was shown to increase the long-lived effector-memory
CD8 T cell pool.10 CD8 T cells with memory potential are superior to terminally differentiated effector
cells in mediating successful tumor clearance14 as the
latter display impaired proliferation and survival in
vivo, and only mediate short-term anti-tumor effects.
Thus, to monitor only sustained memory T cells that
have enhanced proliferative potential and survival and
the potential to provide more robust and enduring
protection against tumors, we assess CD8 T cell immunological endpoints 14 days after injection of efti, that
is, just before the next efti injection and long after efti
has disappeared from the blood stream. We observed
sustained increases in activated CD4 or CD8 T counts
that are detected at 3 or 6 months in patients injected
with 30 mg efti. These increases are different from what
to expect from pembrolizumab monotherapy where
activated CD8 T cell counts are increased only early on,
at 2 or 4 weeks after start of treatment.15 Failed T cell
priming often needs repair through APC activation16
before successful sensitization to PD-1/PD-L1 blockade
and MHC II agonism with efti plays a critical role in
generating T cell immunity by activating DCs6–8
As efti or any other MHC class II agonist has not been
tested yet in combination with an anti-PD-1 therapy,
patients started efti injections in part A of the study
at cycle 5 of pembrolizumab in order not to expose
8

the subset of patients with pembrolizumab-
induced
immune-related AEs in the first 3 months of exposure
to a second immunostimulant. Then, as no new safety
signals were seen in part A, part B patients were treated
with the combination from day 1 on. No new safety
signals or DLTs emerged from the study data reported
in part A or part B. Low numbers of patients reported
injection-site reactions, which typically reappeared on
multiple administrations, and this is consistent with the
proposed mechanism of action (ie, APC activation of s.c
DCs or Langerhans cells in the dermis) and the known
safety profile of efti. There was no indication that efti
induces immune-related AEs or increases the severity of
pembrolizumab-related immune-related AEs.
When analyzing pooled data from parts A and B
with the baseline at start of pembrolizumab therapy,
the irORR was 54%. In large historical studies with
treatment naïve KEYNOTE-006 patients, a 36% ORR,
median PFS of 4.1 months and 47% progression free
at 6 months were reported with pembrolizumab
monotherapy. In patients pretreated with ipilimumab
(KEYNOTE-002), a 21% ORR, median PFS of 2.9
months and 34% progression free at 6 months were
reported with pembrolizumab monotherapy.17 In the
first phase I trial (Keynote-001), 173 melanoma patients
pretreated with ipilimumab or BRAF/MEK inhibitor
received pembrolizumab at 2 mg/kg or 10 mg/kg and
the ORR was 24% in the extension part of the trial.18
Given the late stage population and pre-exposure with
pembrolizumab prior to trial start in part A, the data
reported here are encouraging. A phase II trial study
testing this combination therapy in first and second-line
non-small cell lung cancer and in second-line head and
neck squamous cell cancer is ongoing (NCT03625323).
In this umbrella phase II trial, patients are not selected
for PD-L1 expression levels at the tumor site before enrolment. Thus, “hot” (>50% PD-L1 expression) “tepid” (1%
to 49% PD-L1) or “cold” (<1% PD-L1) tumor patients are
being enrolled (ie, a PD-L1 all-comer trial).
Combination therapies are currently being evaluated
clinically with the goal of enhancing overall antitumor
activity, in order to provide better treatment for patients
with large tumor burdens. The vast majority of trials is
testing a double ICI combination (eg, an anti-CTLA-4,
anti-
LAG-3 or anti-
TIGIT with an anti-
PD-1), preferably in “hot” tumor patients, as blocking two inhibitory
receptors on T cells might be better than just blocking
one receptor. Our approach, combining an APC activator with an ICI, is different as efti, as an MHC class II
agonist, activates T cells through an indirect and physiological mechanism, that is, efti-activated APCs give the
“license to kill”19 to CD8 memory T cells. This may result
in more “tepid” or “cold” tumor patients responding
to the combination therapy. The addition of efti to
pembrolizumab induces long-
term tumor responses
and long-
term increase in circulating activated CD8
and CD4 T cell counts at the 30 mg dose. Importantly,
this immunostimulatory effect was obtained without
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clinically significant toxicity of this first-in-class immunopotentiator targeting MHC class II+ APCs

and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the use
is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
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